Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HuMAB companies -- Ignore unavailable to you. Want to Upgrade?

To: tnsaf who wrote (737)	7/21/2005 9:24:06 PM
From: Steve Lokness	Read Replies (1) \| Respond to of 1022

Quoting from the August issue of Scientific American;....."A recent analysis by Mark C. Via, published by Cambridge Healthtech Advisors, concluded that demand for monoclonal antibodies most likely will far outstrip production capacity for years to come. All these factors conspire to drive up the price of antibody therapies". Comments? Therapies aside, who will likely benefit from restricted production capacity? Appreciate comments. Thanks! steve